Targeted therapy in biliary tract cancer: 2009 update. (Q37650623)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20001803%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

review article

1 reference

title

Targeted therapy in biliary tract cancer: 2009 update (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20001803%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20001803%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Bruno Vincenzi

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20001803%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Daniele Santini

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20001803%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

2

Vladimir Virzì

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20001803%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Maria Elisabetta Fratto

series ordinal

3

object named as

Maria Elisabetta Fratto

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20001803%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

language of work or name

English

0 references

publication date

1 December 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20001803%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20001803%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20001803%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20001803%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

1675-1684

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20001803%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

cites work

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

The epidemiology of cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

Guidelines for chemotherapy of biliary tract and ampullary carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

Role of radiation after operative palliation in cancer of the proximal bile ducts

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

Systemic therapy for biliary tract cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

The ErbB/HER receptor protein-tyrosine kinases and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

ERBB receptors and cancer: the complexity of targeted inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

The ErbB receptors and their ligands in cancer: an overview.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

ErbB receptors: new insights on mechanisms and biology

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

Future therapies for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

Bile acids activate EGF receptor via a TGF-alpha-dependent mechanism in human cholangiocyte cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

Angiogenesis in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

The role of thymidine phosphorylase and thrombospondin-1 in angiogenesis and progression of intrahepatic cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

Comparative protein expression profiles of hilar and peripheral hepatic cholangiocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

The role of angiogenesis inhibitors in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

Disrupting insulin-like growth factor signaling as a potential cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

The therapeutic potential of agents targeting the type I insulin-like growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

Expression of IGF-II in early experimental hepatocellular carcinomas and its significance in early diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

AKT and ERK1/2 signaling in intrahepatic cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

New drug development in digestive neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

Targeting mammalian target of rapamycin (mTOR) for health and diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

Bortezomib as an antitumor agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

Proteasome inhibition-induces endoplasmic reticulum dysfunction and cell death of human cholangiocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

Phase II study of erlotinib in patients with advanced biliary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.130

21 January 2018

Identifiers

DOI

10.2217/FON.09.130

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20001803%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference